Live Breaking News & Updates on லிம்போமா கூட்டணி யூரோப்
Stay updated with breaking news from லிம்போமா கூட்டணி யூரோப். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
RESILIENCE project aims to reduce the burden of cardiovascular disease in cancer survivors Cancer patients are a vulnerable population prone to develop cardiovascular complications. Among other factors, some anticancer therapies can induce adverse cardiovascular effects. Every year, more than 3 million Europeans receive anthracyclines alone or in combination with other anticancer agents. Anthracyclines are a frequently prescribed anticancer agent that can induce an irreversible toxic effect on the heart may lead to chronic heart failure in ≈5% of the cases. It is estimated that in Europe the prevalence of chronic heart failure secondary to cancer therapy-related cardiotoxicity is ≈1 million people. The trade-off between cancer and chronic heart failure is a massive psychological burden. For healthcare systems, the growing incidence of chronic heart failure has devastating consequences. ....
European Society of Cardiology Madrid, 30 June 2021. Cancer patients are a vulnerable population prone to develop cardiovascular complications. Among other factors, some anticancer therapies can induce adverse cardiovascular effects. Every year, more than 3 million Europeans receive anthracyclines alone or in combination with other anticancer agents. Anthracyclines are a frequently prescribed anticancer agent that can induce an irreversible toxic effect on the heart may lead to chronic heart failure in ≈5% of the cases. It is estimated that in Europe the prevalence of chronic heart failure secondary to cancer therapy-related cardiotoxicity is ≈1 million people. The trade-off between cancer and chronic heart failure is a massive psychological burden. For healthcare systems, the growing incidence of chronic heart failure has devastating consequences. ....
NICE uphold appeal by Kyowa Kirin, for POTELIGEO in the treatment of those living with certain ultra-rare blood cancers The National Institute for Health and Care Excellence (NICE) has upheld an appeal ....
Kyowa Kirin Responds to the National Institute for Health and Care Excellence (NICE) Decision to Not Provide People Living With Certain Rare Blood Cancers Access to POTELIGEO (mogamulizumab) two very rare forms of non-Hodgkin lymphoma will not have access to an innovative systemic treatment following NICE s decision to not recommend mogamulizumab for routine use in the NHS . Kyowa Kirin is disappointed by this decision but remains committed to finding a resolution with NICE. The National Institute for Health and Care Excellence (NICE) today published its final appraisal document (FAD) for POTELIGEO (mogamulizumab) announcing that POTELIGEO will not be made available on the NHS ....